GRI Bio Inc (GRI)

Form 8-K - Current report

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S...

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register...

Form 8-K - Current report

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation...

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

– Live video webcast on Wednesday, February 11th at 1:00 PM EST  LA JOLLA, CA, Feb. 05, 2026 (GLOBE...

Form 8-K - Current report

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5...

Form EFFECT - Notice of Effectiveness

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report